---
date: "2024-01-13 15:00:00" # 2021-07-14
title: "7 Incredible Reasons to Invest in Pfizer Stock Today: Unlocking the Potential of a Pioneering Pharmaceutical Giant"
# image: "images/plots/{{titleSlag}}.png"
author: "justin-guese"
draft: false
---
tickers: <a href='https://finance.yahoo.com/quote/PFE' target='_blank'>PFE</a> 

source: <a href='https://www.fool.com/investing/2024/01/13/7-reasons-to-buy-pfizer-stock/' target='_blank'>Motley Fool</a>

#### tickers affected by this

| ticker | polarity | why? |
|------------|------------|------------|
| PFE | positively | The recent string of FDA approvals and a diverse product portfolio can positively impact Pfizer's stock (PFE) by driving future revenue growth and enhancing innovation. Additionally, the company's reasonable valuation and strong track record make it an attractive investment. |



#### our strategies and bots using these tickers

None so far...

## summary

## 7 Incredible Reasons to Buy Pfizer Stock Right Now

Pfizer, despite its recent struggles in the stock market, has accomplished impressive feats, setting the stage for future success. Here are seven compelling reasons to consider investing in Pfizer stock:

1. An incredible string of approvals: Last year, Pfizer secured seven new approvals from the U.S. Food and Drug Administration (FDA). This is an unusually high number for the company, considering it usually only achieves one or two new launches annually. The FDA's approval of 66 new drugs, vaccines, and biologics in 2023, with seven going to Pfizer, demonstrates the company's innovative potential.

2. Diverse product portfolio: Pfizer's newer products, such as Zavzpret for migraines and Paxlovid for COVID-19, will contribute to future revenue growth. The company's pipeline of programs, coupled with its acquisition of Seagen, an oncology specialist, expands its product offerings and enhances innovation.

3. Reasonable valuation: Despite the stock's recent poor performance, Pfizer is attractively valued. With a forward price-to-earnings ratio of 13.1, compared to the pharmaceutical industry's 17.1, the stock presents a compelling investment opportunity.

4. Solid dividend stock: Pfizer's dividend program offers investors a reliable income stream. Dividend payments provide stability and can offset short-term stock price fluctuations.

5. Potential for future growth: Pfizer's innovative pipeline and acquisitions indicate a commitment to long-term growth. The company's rejuvenating lineup positions it well for future success, which may be realized with patience and a long-term investment perspective.

6. Strong track record: Pfizer is a well-established pharmaceutical giant with a long history of success. Investors can have confidence in the company's ability to navigate challenges and adapt to evolving market conditions.

7. Market-leading position: Pfizer's strong brand recognition and market-leading position in the pharmaceutical industry contribute to its stability and potential for growth.

It's important to note that investing in any individual stock carries risks. Investors should conduct thorough research, consider their investment goals, and consult with a financial advisor before making any investment decisions.

*Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy.*

## Related Articles

- 2 Red Flags That Could Sink Pfizer in 2024
- Is Pfizer Stock a Buy Now?
- Will Pfizer's Stock Bounce Back in 2024?
- 3 Magnificent High-Yield Dividend Stocks to Buy in 2024
- Could Pfizer Be a No-Brainer Stock to Buy Right Now, Even If Its COVID Sales Continue to Plunge?